Pharma
major Lupin has received tentative approval for its Abacavir Sulfate
and Lamivudine tablets from the USFDA to market generic version of ViiV
Healthcare company's Epzicom tablets.
"Lupin's Abacavir Sulfate and Lamivudine tablets, 600 mg/300 mg are the AB rated generic equivalent of ViiV Healthcare company's Epzicom tablets, 600 mg/300 mg.
"Abacavir Sulfate and Lamivudine tablets, 600 mg/300 mg in combination with other antiretroviral agents are indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection," a company statement said today.
The statement further said, "We have received tentative approval from USFDA for Abacavir Sulfate and Lamivudine tablets, to market a generic version of ViiV Healthcare company's Epzicom tablets."
Epzicom tablets had the US sales of $426 million.
The company is a significant player in cardiovascular, diabetology, asthma, paediatric and anti-infective space and holds global leadership position in the Anti-TB segment.
"Lupin's Abacavir Sulfate and Lamivudine tablets, 600 mg/300 mg are the AB rated generic equivalent of ViiV Healthcare company's Epzicom tablets, 600 mg/300 mg.
"Abacavir Sulfate and Lamivudine tablets, 600 mg/300 mg in combination with other antiretroviral agents are indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection," a company statement said today.
The statement further said, "We have received tentative approval from USFDA for Abacavir Sulfate and Lamivudine tablets, to market a generic version of ViiV Healthcare company's Epzicom tablets."
Epzicom tablets had the US sales of $426 million.
The company is a significant player in cardiovascular, diabetology, asthma, paediatric and anti-infective space and holds global leadership position in the Anti-TB segment.
No comments:
Post a Comment